Manteio Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Manteio Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,511	Closed	-$447K	–	101
2021 Q4	$447K	Buy	+3,511	New	+$461K	0.58%	34

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Manteio Capital's JAZZ Position: Q1 2022 in Review

Manteio Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2022, closing a stake of 3,511 shares — an estimated $447K sold.

Manteio Capital first reported a position in JAZZ in Q4 2021 and held it in 1 quarter. The position peaked at $447K in Q4 2021. 462 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

Manteio Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Manteio Capital sold 3,511 Jazz Pharmaceuticals shares in Q1 2022, an estimated $447K.
Manteio Capital first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Manteio Capital's Jazz Pharmaceuticals position peaked at $447K in Q4 2021.
462 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on Manteio Capital's 13F filing for Q1 2022.